☰

Diana J. Azzam, Ph.D. - Publications

Affiliations: 
2012 Biochemistry and Molecular Biology (Medicine) University of Miami, Coral Gables, FL 
Area:
Biochemistry, Medicine and Surgery, Molecular Biology, Cell Biology, Oncology
Tree Info Grants Similar researchers PubMed Report error

22 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2022 Kurani H, Razavipour SF, Harikumar KB, Dunworth M, Ewald AJ, Nasir A, Pearson G, van Booven D, Zhou Z, Azzam D, Wahlestedt C, Slingerland J. DOT1L is a novel cancer stem cell target for triple negative breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 35135840 DOI: 10.1158/1078-0432.CCR-21-1299  0.676
2019 Lohse I, Azzam DJ, Al-Ali H, Volmar CH, Brothers SP, Ince TA, Wahlestedt C. Ovarian Cancer Treatment Stratification Using Drug Sensitivity Testing. Anticancer Research. 39: 4023-4030. PMID 31366484 DOI: 10.21873/Anticanres.13558  0.458
2018 Simpkins F, Jang K, Yoon H, Hew K, Kim M, Azzam DJ, Sun J, Zhao D, Ince TA, Liu W, Guo W, Wei Z, Zhang G, Mills GB, Slingerland JM. Dual Src and MEK inhibition decreases ovarian cancer growth and targets tumor initiating stem-like cells. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 29959144 DOI: 10.1158/1078-0432.Ccr-17-3697  0.669
2018 Picon-Ruiz M, Pan C, Drewes-Elger K, Jang K, Besser A, Zaho D, Morata-Tarifa C, Kim M, Ince T, Azzam D, Wander S, Cote R, Guy H, El-Ashry D, Torne-Poyatos P, et al. Abstract P6-05-01: Interactions between adipocytes and breast cancer cells stimulate cytokine production and drive Src/SOX2/miR-302b mediated malignant progression Cancer Research. 78. DOI: 10.1158/1538-7445.Sabcs17-P6-05-01  0.724
2017 Ince T, Witt A, Lee C, Lee T, Azzam D, Wang B, Caslini C, Petrocca F, Grosso J, Jones M, Cohick E, Gropper A, Wahlestedt C, Richardson A, Shiekhattar R, et al. Abstract P5-07-13: Identification of a cancer stem sell-specific function for the histone deacetylases, HDAC1 and HDAC7, in breast and ovarian cancer Cancer Research. 77. DOI: 10.1158/1538-7445.Sabcs16-P5-07-13  0.51
2017 Shahin L, Cubedo E, Coats E, Boyd J, Azzam D. Abstract 1906: The role of immunogenic SPANX antigens in distinct cancer stem cell subsets within triple negative breast cancers Cancer Research. 77: 1906-1906. DOI: 10.1158/1538-7445.Am2017-1906  0.637
2016 Ariazi EA, Taylor JC, Black MA, Nicolas E, Slifker MJ, Azzam DJ, Boyd J. A New Role for ERα: Silencing via DNA Methylation of Basal, Stem Cell, and EMT Genes. Molecular Cancer Research : McR. PMID 28108626 DOI: 10.1158/1541-7786.Mcr-16-0283  0.53
2016 Witt AE, Lee CW, Lee TI, Azzam DJ, Wang B, Caslini C, Petrocca F, Grosso J, Jones M, Cohick EB, Gropper AB, Wahlestedt C, Richardson AL, Shiekhattar R, Young RA, et al. Identification of a cancer stem cell-specific function for the histone deacetylases, HDAC1 and HDAC7, in breast and ovarian cancer. Oncogene. PMID 27694895 DOI: 10.1038/Onc.2016.337  0.483
2016 Picon-Ruiz M, Pan C, Drews-Elger K, Jang K, Besser AH, Zhao D, Morata-Tarifa C, Kim M, Ince TA, Azzam DJ, Wander SA, Wang B, Ergonul B, Datar RH, Cote RJ, et al. Interactions between Adipocytes and Breast Cancer Cells Stimulate Cytokine Production and Drive Src/Sox2/miR-302b-Mediated Malignant Progression. Cancer Research. PMID 26744520 DOI: 10.1158/0008-5472.Can-15-0927  0.771
2015 Zhao D, Pan C, Sun J, Gilbert C, Drews-Elger K, Azzam DJ, Picon-Ruiz M, Kim M, Ullmer W, El-Ashry D, Creighton CJ, Slingerland JM. VEGF drives cancer-initiating stem cells through VEGFR-2/Stat3 signaling to upregulate Myc and Sox2. Oncogene. 34: 3107-19. PMID 25151964 DOI: 10.1038/Onc.2014.257  0.654
2015 Simpkins F, Hew K, Azzam D, Wei Z, Zhang G, Sun J, Zhang D, Jang K, Liu W, Lu Y, Mills G, Tan I, Slingerland J. Abstract POSTER-THER-1431: Combined Src and MEK inhibition decreases ovarian cancer (OVCA) cell growth, tumorigenicity and aldehyde dehydrogenase positive tumor-initiating-cells Clinical Cancer Research. 21. DOI: 10.1158/1557-3265.Ovcasymp14-Poster-Ther-1431  0.669
2014 Boelens MC, Wu TJ, Nabet BY, Xu B, Qiu Y, Yoon T, Azzam DJ, Twyman-Saint Victor C, Wiemann BZ, Ishwaran H, Ter Brugge PJ, Jonkers J, Slingerland J, Minn AJ. Exosome transfer from stromal to breast cancer cells regulates therapy resistance pathways. Cell. 159: 499-513. PMID 25417103 DOI: 10.1016/J.Cell.2014.09.051  0.688
2014 Drews-Elger K, Brinkman JA, Miller P, Shah SH, Harrell JC, da Silva TG, Ao Z, Schlater A, Azzam DJ, Diehl K, Thomas D, Slingerland JM, Perou CM, Lippman ME, El-Ashry D. Primary breast tumor-derived cellular models: characterization of tumorigenic, metastatic, and cancer-associated fibroblasts in dissociated tumor (DT) cultures. Breast Cancer Research and Treatment. 144: 503-17. PMID 24567196 DOI: 10.1007/S10549-014-2887-9  0.661
2014 Azzam D, Wahlestedt C, Slingerland J. Abstract 3042: Therapeutic targeting of distinct subsets of cancer stem cells within triple negative breast cancers Cancer Research. 74: 3042-3042. DOI: 10.1158/1538-7445.Am2014-3042  0.716
2013 Azzam DJ, Zhao D, Sun J, Minn AJ, Ranganathan P, Drews-Elger K, Han X, Picon-Ruiz M, Gilbert CA, Wander SA, Capobianco AJ, El-Ashry D, Slingerland JM. Triple negative breast cancer initiating cell subsets differ in functional and molecular characteristics and in γ-secretase inhibitor drug responses. Embo Molecular Medicine. 5: 1502-22. PMID 23982961 DOI: 10.1002/Emmm.201302558  0.742
2013 Simpkins F, Azzam D, Slingerland JM. Abstract B50: Preclinical efficacy of combined MEK and Src inhibition: MEK inhibitor reverses resistance to Src inhibitor therapy in ovarian cancer cells Clinical Cancer Research. 19. DOI: 10.1158/1078-0432.Ovca13-B50  0.707
2012 Simpkins F, Hevia-Paez P, Sun J, Ullmer W, Gilbert CA, da Silva T, Pedram A, Levin ER, Reis IM, Rabinovich B, Azzam D, Xu XX, Ince TA, Yang JY, Verhaak RG, et al. Src Inhibition with saracatinib reverses fulvestrant resistance in ER-positive ovarian cancer models in vitro and in vivo. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 5911-23. PMID 22896656 DOI: 10.1158/1078-0432.Ccr-12-1257  0.76
2012 Azzam DJ, Elger KD, Zhao D, Ranganathan P, Capobianco T, Minn AJ, Creighton C, Picon M, Sun J, Pan C, Wander SA, Ashry DE, Slingerland JM. Abstract 3478: CD44+CD24low+progenitors in ER negative breast cancer have higher Notch1 activation, self-renewal, and chemo resistance and generate CD44+CD24negcells and tumors that metastasize Cancer Research. 72: 3478-3478. DOI: 10.1158/1538-7445.Am2012-3478  0.758
2012 Boelens MC, Wu TJ, Yoon T, Azzam D, Slingerland JM, Minn AJ. Abstract 1505: Stroma-mediated DNA damage resistance of human breast cancer Cancer Research. 72: 1505-1505. DOI: 10.1158/1538-7445.Am2012-1505  0.722
2011 Chen Y, Alvarez EA, Azzam D, Wander SA, Guggisberg N, Jordà M, Ju Z, Hennessy BT, Slingerland JM. Combined Src and ER blockade impairs human breast cancer proliferation in vitro and in vivo. Breast Cancer Research and Treatment. 128: 69-78. PMID 20669046 DOI: 10.1007/S10549-010-1024-7  0.765
2011 Azzam DJ, Drews-Elger K, Zhao D, Chendong P, Wander SA, El-Ashry D, Slingerland JM. Abstract 3335: Self-renewal, tumorigenicity and metastatic potential of CD44+ cells in ER-negative lines and dissociated primary human breast cancers is increased in CD24+ subsets Cancer Research. 71: 3335-3335. DOI: 10.1158/1538-7445.Am2011-3335  0.744
2011 Drews-Elger K, Brinkman JA, Azzam DJ, Schlater A, Diehl KM, El-Ashry D. Abstract 2392: Primary cultures established from estrogen receptor negative breast tumors: Method and characterization Cancer Research. 71: 2392-2392. DOI: 10.1158/1538-7445.Am2011-2392  0.585
Show low-probability matches.